Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Ross Berkowitz, MD, is the co-director of the New England Trophoblastic Disease Center at Dana-Farber Brigham Cancer Center, affiliated with the Susan F. Smith Center for Women's Cancers. For more than 30 years, Dr. Berkowitz has focused his research and care on GTD, and has published more than 250 original reports and reviews on this disease
– including his studies of risk factors and improved therapies.
Neil Horowitz, MD, is a board certified gynecologic oncologist who practices closely with the founders of the New England Trophoblastic Disease Center and is the chair of the GTD subcommittee of NRG Oncology,
and is considered an international expert. As Director of Clinical Research in Gynecologic Oncology, Dr. Horowitz's work has included several ongoing research projects on GTD and evaluating novel therapies for this disease.
Kevin Elias, MD, is a gynecologic oncologist actively involved in the treatment of GTD. As Director of the Gynecologic Oncology Laboratory, he leads basic science research into the biology
of GTD including understanding chemotherapy resistance and developing novel therapies.
Your entire care team has extensive experience in caring for patients with gynecologic cancers. Our specialists work closely together and collaborate regularly to ensure that your care plan offers the best possible outcomes and that all your needs are
Learn more about our team of gynecological cancer specialists.
New Patient Appointments